Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study
IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)– Agendia, Inc., a leader in innovative genomic testing for breast cancer, today announced the publication of new findings in JNCI...